Gilead Sciences stock heads into the open after a 0.7 percent dip
Published on 09/10/2026 at 08:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock closed at USD 145.65 on the Nasdaq on September 9, 2026, down 0.7 percent from the prior session based on data reported at 4:00 p.m. Eastern. Per Nasdaq data compiled by MarketBeat, the shares traded modestly lower while remaining well above levels seen earlier in the year.
September 9, 2026 in numbers
Gilead Sciences Inc. (ISIN US3755581036, Nasdaq: GILD) saw its stock move within a relatively tight intraday range on September 9, 2026, with the close at USD 145.65 sitting between the session low and high on the Nasdaq. According to price data summarized by MarketBeat, the latest 52-week performance shows the shares up roughly 18.7 percent from an earlier reference point in the year, underscoring that the recent 0.7 percent decline came from a higher base. In the same session, major U.S. equity benchmarks also weakened, with the S&P 500 falling about 0.5 percent and the Nasdaq Composite losing around 0.6 percent, so Gilead traded in a generally softer market backdrop.
Beyond the headline numbers, the stock’s recent gains relative to its earlier levels this year suggest that investors had previously marked up Gilead’s valuation before the latest pullback. Broader market wraps for September 9, 2026 noted that U.S. stocks ended lower as selling pressure hit several sectors, including parts of healthcare, which framed the move in Gilead within a wider risk-off tone. The S&P 500 closed lower and the Dow Jones Industrial Average dropped around 0.8 percent that day, indicating that Gilead’s modest decline roughly matched the market’s direction.
Conference update shapes today
Today’s session follows closely on Gilead’s appearance at the Wells Fargo 21st Annual Healthcare Conference, where the company outlined an expanded growth plan emphasizing its HIV franchise alongside oncology and inflammation programs. As Investing.com reported on September 9, 2026, management used the conference to highlight diversification in its pipeline and revenue drivers, a theme that may remain in focus for investors heading into the open today. A detailed transcript of the conference discussion, carried by TradingView, emphasizes upcoming launches and data readouts in HIV, oncology and inflammation, which could influence sentiment around the stock today even though no specific earnings release or major corporate event is due.
